LD-2 disclosure · 4th Quarter - Report
ENDO PHARMACEUTICALS
Client
- Description
- Pharmaceutical Company
- Location
- District of Columbia · United States of America
Registrant
- Description
- Government Relations Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesHealth Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. Issues relating to Medicare Part D rebates. Issues relating to health information technology. Compounding and drug supply chain legislation. H.R.471 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015 Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to the availability of epinephrine. General Health issues, including but not limited to, coverage and reimbursement; drug
LobbyistsDAVID JORY · BRIAN SUTTER · CHRISTOPHER BOWLIN
Covered position (BRIAN SUTTER): Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02
TargetedSENATE · HOUSE OF REPRESENTATIVES
Taxation/Internal Revenue Code
H.R. 160- Protect Medical Innovation Act of 2015 H.Res106 Prostate Cancer Survivors Quality of Life Act Medical Device Tax Repeal Stop Corporate Inversions Act S.2360, H.R.4679
LobbyistsDAVID JORY · BRIAN SUTTER · CHRISTOPHER BOWLIN
Covered position (BRIAN SUTTER): Staff Dir., W&M Health Subcommittee, Chrman Dave Camp April'13-Dec.'14 Professional Staff, W&M Health Subcommittee, Chrman Dave Camp, Jan'11-April'13 Leg Dir. Rep. Dave Camp, May'08-Jan'11 Leg Asst Rep. Dave Camp, Feb'03-May'08; Staff Ast July'02-